AERI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Nov 2022 @ 16:00):

Stats
Today's Volume	1.22M
Average Volume	786 842
Market Cap	0.00
EPS	$-0.560 ( Q3 \| 2022-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 30.78
ATR14	$0.0770 (0.50%)

AERI 0.00%

ALVO 1.64%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 61.54%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO -1.30%

INDV -2.30%

JUPWW -20.00%

LFCR -7.99%

LNDC -3.52%

LSDI -23.29%

PRFX 1.50%

PROCW 10.09%

QLI 4.26%

SBFMW 1.43%

SHOT 2.59%

SHPH 0.18%

Insider Trading

Date	Person	Action	Amount	type
2022-11-21	Mchugh Julie	Sell	16 854	Stock Option (right to buy)
2022-11-21	Mcgraw Benjamin F Iii	Sell	16 854	Stock Option (right to buy)
2022-11-21	Mcdonnell Peter J	Sell	16 854	Stock Option (right to buy)
2022-11-21	Kopczynski Casey C.	Sell	65 941	Stock Option (right to buy)
2022-11-21	Lang Peter Frederick	Sell	160 551	Stock Option (right to buy)

INSIDER POWER
-99.57
Last 98 transactions
Buy: 1 757 162 \| Sell: 988 060

Volume Correlation

Long: 0.16 (neutral)

Short: 0.47 (neutral)

Signal:(68.342) Neutral

Aerie Pharmaceuticals, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aerie Pharmaceuticals, Correlation - Currency/Commodity

-0.24
( neutral )

-0.09
( neutral )

-0.59
( weak negative )

0.38
( neutral )

0.92
( very strong )

0.37
( neutral )

Aerie Pharmaceuticals, Financials

Annual	2021
Revenue:	$194.13M
Gross Profit:	$167.29M (86.17 %)
EPS:	$-1.610

FY	2021
Revenue:	$194.13M
Gross Profit:	$167.29M (86.17 %)
EPS:	$-1.610

FY	2020
Revenue:	$83.14M
Gross Profit:	$57.81M (69.53 %)
EPS:	$-3.99

FY	2019
Revenue:	$69.89M
Gross Profit:	$65.06M (93.08 %)
EPS:	$-4.39

Financial Reports:

No articles found.

Aerie Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aerie Pharmaceuticals,

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.